Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

Regeneron signed on a GLP-1/GIP candidate from China's Hansoh Pharma. And more. Summit Therapeutics unveiled the first global phase 3 readout from Akeso’s PD-1xVEGF bispecific ivonescimab ...

Regeneron Pharmaceuticals just took a hit on Wall Street, with shares dropping to a new 52-week low. UBS Group revised its price target down from $633 to $560 and gave the stock a neutral rating. That ...

Regeneron Pharmaceuticals ... Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process ...

When Regeneron announced its acquisition of the company’s assets last month, it pledged to adhere to privacy laws and consumer policies regarding the genetic database—a commitment that TTAM ...

Voorhees reported consulting or advisory roles with AbbVie/Genentech, Bristol Myers Squibb, Pfizer, Sanofi, Janssen, GSK, Regeneron, Ascentage Pharma, AstraZeneca, and Kite, and research funding ...

Yancopoulos, MD, PhD, board co-chair, president, chief scientific officer, Regeneron, in a press release. The randomized, double-blind COURAGE trial evaluated the efficacy and safety of trevogrumab, ...

The oral drug candidate aims to rival Sanofi and Regeneron’s blockbuster therapy, Dupilumab, which recorded $11.6 billion in global sales in 2023. The trial tested the safety and efficacy of ...

Regeneron is widening its clinical-stage obesity portfolio. Credit: lev radin/Shutterstock. Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure ...